Cardiol Therapeutics (CRDL) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Organigram Global (OGI) over the past year, gaining 24.5% versus a loss of 51.0%. Over five years, CRDL leads with a -66.4% price change compared with -89.3% for OGI. Cardiol Therapeutics is the larger company by market cap ($157.4 million vs $135.5 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | OGI |
|---|---|---|
| Share price | $1.30 | $0.94 |
| Market cap | $157.36M | $135.50M |
| 1-day change | -1.89% | -2.08% |
| YTD return | +38.36% | -42.86% |
| 1-year return | +24.53% | -51.02% |
| 5-year return | -66.41% | -89.29% |
| P/E ratio (TTM) | — | 2.19 |
| Forward P/E | — | 39.17 |
| EPS (TTM) | $-0.25 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $2.24 |
| 52-week low | $0.88 | $0.853 |
| Distance from 52-week high | -44.66% | -58.04% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +545.56% | — |
| Average volume | 1.44M | 882.38K |
| Shares outstanding | 121.51M | 144.15M |
| Employees | 18 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed OGI by 75.5 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
CRDL vs OGI FAQ
Which is bigger, Cardiol Therapeutics or Organigram Global?
Cardiol Therapeutics (CRDL) is larger, with a market capitalization of $157.36M compared with $135.50M for Organigram Global (OGI).
Which stock has performed better over the past year, CRDL or OGI?
CRDL returned +24.53% over the past 12 months, compared with -51.02% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Organigram Global in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cardiol Therapeutics and Biotechnology: Pharmaceutical Preparations for Organigram Global.